Approved natural products-derived nanomedicines for disease treatment

LI **aotong, LAI Yaoyao, WAN Guanghan… - Chinese Journal of …, 2024 - Elsevier
In recent years, there has been an increasing emphasis on exploring innovative drug
delivery approaches due to the limitations of conventional therapeutic strategies, such as …

Immunogenicity and safety of a monovalent omicron XBB. 1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim …

K Alves, K Kotloff, RS McClelland, A Kouassi… - The Lancet Infectious …, 2024 - thelancet.com
Background Authorities globally recommended a monovalent omicron XBB. 1.5-based
COVID-19 vaccine for the 2023–24 season. The Novavax COVID-19 vaccine, NVX …

Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose

PD Yadav, DY Patil - The Lancet Infectious Diseases, 2025 - thelancet.com
The cross-neutralising effects of COVID-19 vaccines given as prime–boost regimens have
garnered much interest as SARS-CoV-2 has evolved. Several studies have shown that …

[HTML][HTML] First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

M Esen, J Fischer-Herr, JJ Gabor, JM Gaile… - Vaccines, 2024 - pmc.ncbi.nlm.nih.gov
The emergence of SARS-CoV-2 has necessitated the development of versatile vaccines
capable of addressing evolving variants. Prime-2-CoV_Beta, a novel Orf virus-based COVID …

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough

Y Yao, Y Yang, Q Wu, M Liu, W Bao, Q Wang… - European Journal of …, 2025 - Springer
Abstract Background The SARS-CoV-2 Omicron variant, since its initial detection, has
rapidly spread across the globe, becoming the dominant strain. It is important to study the …

Immunogenicity and Safety of Gamma, Omicron BA. 4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different …

G Perez-Marc, LM Coria, A Ceballos, JM Rodriguez… - medRxiv, 2024 - medrxiv.org
Abstract Background This study (ARVAC-F2-3-002) assessed the immunogenicity, safety,
and tolerability of a recombinant booster vaccine (ARVAC) containing the receptor binding …

[CITAZIONE][C] Bivalent (Omicron BA. 5/ancestral) recombinant spike protein vaccine: a promising booster

R Zhang, IFN Hung - The Lancet Infectious Diseases, 2024 - thelancet.com
With the emergence of Omicron variants, which carry several immune escape-related
mutations in the spike protein, the effectiveness of COVID-19 prototype vaccines was …